FreeThink Technologies, in collaboration with Lhasa Limited, is proud to present the annual Science of Stability (SOS) Conference, taking place 27–29 April 2026, in Glasgow, Scotland. This conference brings together industry leaders and innovators from across the pharmaceutical and related industrial areas to explore the latest in stability science.
Designed for Pharmaceutical Innovators
SOS is the industry’s leading forum for discussions on degradation chemistry (what happens) and accelerated predictive stability (how fast does it occur), and other key stability topics central to modern drug development. Attendees will gain in-depth insights on:
- Advances in accelerated stability testing and modeling approaches for drug products.
- Real-world case studies on degradation pathways, mass balance, and nitrosamine risk management.
- Emerging tools and data techniques for robust stability predictions.
SOS includes both pure scientific presentations and examples of practical, real-world applications to help optimize stability study design, improve control strategies, and accelerate product development timelines.
Connect with Thought Leaders & Peers
The SOS conference features full and rapid-fire presentations, along with ample networking opportunities, providing pharma professionals with the space to share experiences and foster collaboration.
Event Details
- Dates: 27–29 April 2026
- Location: Glasgow, Scotland
- Learn More & Register: www.stabilityconference.com/sos-conference/
Don’t miss this chance to be part of the stability science conversation shaping the future of pharmaceutical development. Secure your spot today!
Featured Speakers
- Sara Ryan and Matthew Chan, AstraZeneca: “Novel Application of Accelerated Predictive Stability Modelling for Peptide and Oligonucleotide Drug Products: Early Case Studies”
- Mike Urquhart Urqhart, GSK: “Enhancements to the N-nitrosamine risk assessment process”
- Janina S. Steeger, UCB Biosciences: “Exploratory Studies of Excipient-Driven Stability in Solid Dosage Forms via Accelerated Predictive Stability”
- Eduardo De La Toba, Pfizer: “Hydrogen Peroxide Stress Testing: A Systematic Evaluation of Key Experimental Parameters for Probing Relevant and Non-Relevant Oxidation Pathways”
- Tomke Mueller, AbbVie: “Chemical Stability in Amorphous Solid Dispersions”
- Garry Scrivens, Viatris: “Modelling physical stability phenomena relevant to inhaled dosage forms”